Heron Therapeutics, Inc. — Q3 2017 Form 10-Q Summary
Business context and reporting period
Heron is a commercial-stage biotechnology company developing therapies for cancer-related nausea and vomiting and postoperative pain. The filing covers the three and nine months ended September 30, 2017; financial statements are unaudited.
- SUSTOL: FDA-approved extended-release granisetron product; U.S. commercial sales began in October 2016.
- CINVANTI: Intravenous aprepitant product candidate; FDA NDA review was pending with a November 12, 2017 PDUFA goal date.
- HTX-011: Long-acting bupivacaine/meloxicam product candidate for postoperative pain; Phase 3 development had begun.
Financial performance and position
| Metric | Q3 2017 | Q3 2016 | 9M 2017 | 9M 2016 |
|---|---|---|---|---|
| Net product sales | $8.6 million | None | $20.7 million | None |
| Cost of product sales | $1.1 million | None | $3.3 million | None |
| Gross margin | Approximately 87.7% | Not meaningful | Approximately 84.3% | Not meaningful |
| Research and development | $28.8 million | $30.2 million | $90.8 million | $73.6 million |
| General and administrative | $6.5 million | $5.3 million | $19.4 million | $15.5 million |
| Sales and marketing | $13.5 million | $12.2 million | $39.9 million | $35.0 million |
| Net loss | $(41.9) million | $(48.5) million | $(135.0) million | $(125.2) million |
| Net loss per share | $(0.77) | $(1.24) | $(2.55) | $(3.34) |
| Operating cash flow | $(40.5) million | $(36.1) million | $(123.2) million | $(95.6) million |
Q3 operating loss was $41.3 million, equivalent to an operating margin of approximately negative 481.8%. The nine-month operating loss was $132.7 million, or approximately negative 640.5% of revenue. These margins are distorted by the early commercial launch and substantial development spending.
- Cash and cash equivalents were $65.5 million at September 30, 2017, compared with $13.4 million at December 31, 2016.
- Short-term investments were $8.5 million, producing total cash, cash equivalents and short-term investments of approximately $74.0 million versus $51.1 million at year-end 2016.
- Accounts receivable increased to $28.9 million from $2.0 million, with most expected to be collected in Q4 2017 and Q1 2018.
- Deferred revenue was $5.6 million, representing SUSTOL shipments not yet recognized under the sell-through revenue approach.
- Total liabilities were $78.1 million and stockholders’ equity was $40.1 million at September 30, 2017, compared with a $21.3 million stockholders’ deficit at December 31, 2016.
- The company had $25.0 million outstanding under its related-party promissory note and $6.3 million of principal under convertible notes, carried at $3.5 million net of discount.
Material changes versus the prior comparable period
- SUSTOL generated $8.6 million of Q3 sales and $20.7 million for the first nine months, compared with no comparable sales in 2016. The company had deferred $5.6 million of customer shipments at quarter-end.
- R&D increased 23% for the first nine months, primarily from higher HTX-011 spending of $17.5 million and CINVANTI spending of $6.9 million. Q3 R&D declined modestly because of lower SUSTOL-related, personnel and stock-based compensation costs, partially offset by higher HTX-011 costs.
- Sales and marketing increased to support SUSTOL commercialization, CINVANTI launch preparation and HTX-011 market planning.
- Nine-month net loss increased by $9.8 million, and operating cash use increased by $27.6 million, reflecting expanded development activity and working-capital needs related to the SUSTOL launch.
- In January 2017, Heron raised $163.7 million net through a public offering of 14.1 million common shares. It also repaid $25.0 million of promissory-note principal during Q2.
- Stock-based compensation was $23.6 million for the nine months, up from $18.7 million, and unrecognized compensation cost was $62.1 million at quarter-end.
Guidance, outlook, risks and unusual items
- Management expected to begin recognizing SUSTOL revenue using a sell-in approach in Q4 2017 after obtaining sufficient historical data for rebates, returns and chargebacks. Adoption of the new revenue standard in Q1 2018 was expected to result in earlier revenue recognition and have a material effect on the financial statements and disclosures.
- Management expected Q4 2017 R&D expense to increase because of ongoing HTX-011 Phase 2 and Phase 3 activities.
- HTX-011 Phase 3 studies were expected to be completed in the first half of 2018, with an NDA filing expected in 2018. The FDA granted Fast Track designation in October 2017.
- The company incurred a $0.9 million one-time write-off of short-dated inventory in March 2017.
- Realignment-related expenses totaled $9.7 million through September 30, 2017, with approximately $0.2 million remaining; the final payment was expected in Q2 2018.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year of filing because of recurring losses, negative operating cash flow and the need for additional financing. The statements contain no going-concern adjustments.
- Key risks include dependence on successful SUSTOL commercialization, reimbursement and market acceptance, potential generic competition to ALOXI, regulatory approval of CINVANTI, clinical and regulatory uncertainty for HTX-011, reliance on third-party manufacturers and CROs, patent risks, secured-debt covenants and the need for additional capital.
- Two SUSTOL customers each accounted for at least 10% of nine-month revenue, creating customer concentration risk.
Most important facts for investors to verify
- Whether SUSTOL revenue recognition shifted to the planned sell-in method in Q4 2017 and how sales allowances, rebates, returns and chargebacks affected reported revenue.
- The FDA outcome and commercial timing for CINVANTI following the November 12, 2017 PDUFA date.
- HTX-011 Phase 3 enrollment, results, costs and timing of the anticipated 2018 NDA filing.
- Cash burn, collections of the $28.9 million receivable, and the timing and terms of required additional financing.
- Compliance with covenants and repayment requirements for the secured convertible notes and related-party promissory note.
- The effect of generic ALOXI competition, reimbursement conditions and SUSTOL customer concentration on future sales and gross margins.